Background
Methods
Data source and population sample
Psychotropic drug selection process in the database
Study measures
Statistical analysis
Results
Prescription overview
Gender | Age (years) | Loire Atlantique | Maine et Loire | Mayenne | Sarthe | Vendée | Pays de la Loire (All) | ||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
n
| % Pop |
n
| % Pop |
n
| % Pop |
n
| % Pop |
n
| % Pop 85 |
n
| % Pop | ||
MALE | 0–4 | 4 | 0.01 | 12 | 0.05 | 9 | 0.09 | 4 | 0.02 | - | - | 29 | 0.02 |
5–9 | 89 | 0.21 | 105 | 0.39 | 104 | 0.98 | 35 | 0.19 | 29 | 0.14 | 362 | 0.30 | |
10–14 | 221 | 0.52 | 233 | 0.89 | 183 | 1.75 | 114 | 0.63 | 123 | 0.62 | 874 | 0.74 | |
15–17 | 216 | 0.88 | 170 | 1.14 | 114 | 1.93 | 99 | 0.93 | 108 | 0.98 | 707 | 1.05 | |
Total | 530 | 0.35 | 520 | 0.55 | 410 | 1.10 | 252 | 0.38 | 260 | 0.36 | 1972 | 0.47 | |
FEMALE | 0–4 | 5 | 0.01 | 4 | 0.02 | 2 | 0.02 | 3 | 0.02 | 1 | 0.01 | 15 | 0.01 |
5–9 | 13 | 0.03 | 25 | 0.10 | 15 | 0.15 | 15 | 0.08 | 11 | 0.06 | 79 | 0.07 | |
10–14 | 61 | 0.15 | 97 | 0.38 | 52 | 0.52 | 33 | 0.19 | 23 | 0.12 | 266 | 0.24 | |
15–17 | 113 | 0.48 | 99 | 0.68 | 44 | 0.80 | 61 | 0.58 | 57 | 0.53 | 374 | 0.57 | |
Total | 192 | 0.13 | 225 | 0.25 | 113 | 0.32 | 112 | 0.18 | 92 | 0.13 | 734 | 0.18 | |
ALL | 0–4 | 9 | 0.01 | 16 | 0.03 | 11 | 0.05 | 7 | 0.02 | 1 | <0.01 | 44 | 0.02 |
5–9 | 102 | 0.12 | 130 | 0.25 | 119 | 0.57 | 50 | 0.14 | 40 | 0.10 | 441 | 0.19 | |
10–14 | 282 | 0.34 | 330 | 0.64 | 235 | 1.15 | 147 | 0.41 | 146 | 0.38 | 1140 | 0.50 | |
15–17 | 329 | 0.68 | 269 | 0.91 | 158 | 1.38 | 160 | 0.75 | 165 | 0.75 | 1081 | 0.82 | |
Total | 722 | 0.24 | 745 | 0.40 | 523 | 0.72 | 364 | 0.28 | 352 | 0.25 | 2706 | 0.33 |
Mayenne | Vendée | Sarthe | Maine et Loire | Loire Atlantique | |
---|---|---|---|---|---|
Medical practionner density | 179.8 | 201.3 | 212 | 283.7 | 308.3 |
Rate of AP prescriptions | 0.72 | 0.25 | 0.28 | 0.40 | 0.24 |
CMU-C-affiliated population
Patients with CMU-C affiliation (n) | Patients with NO CMU-C affiliation (n) | Total | Proportion of individuals with CMU-C in general population (%) | 95% CI/Chi2 |
p
| |
---|---|---|---|---|---|---|
Total Pays de la Loire Region | 972 | 1734 | 2706 | 3.7 | 0.34–037/7875.1 | <0.001 |
Loire Atlantique | 250 | 472 | 722 | 4.6 | 0.31–0.38/1476.4 | <0.001 |
Maine et Loire | 255 | 490 | 745 | 4.9 | 0.31–038/1368.8 | <0.001 |
Mayenne | 190 | 333 | 523 | 4.2 | 0.32–0.40/1333.8 | <0.001 |
Sarthe | 132 | 232 | 364 | 6.2 | 0.31–041/560.5 | <0.001 |
Vendée | 122 | 230 | 352 | 3.1 | 0.29–0.39/1156.6 | <0.001 |
AP-specific medication data
Age | Total n = 2706 | |||||||||
---|---|---|---|---|---|---|---|---|---|---|
0–4 y n = 44 | 5–9 y n = 441 | 10–14 y n = 1140 | 15–17 y n = 1081 | |||||||
Antipsychotic type and combination |
n
| % |
n
| % |
n
| % |
n
| % |
n
| % |
SGAP single prescription | 6 | 13.6 | 133 | 30.2 | 392 | 34.4 | 369 | 34.1 | 900 | 33.3 |
FGAP single prescription | 36 | 81.8 | 237 | 53.7 | 447 | 39.2 | 390 | 36.1 | 1110 | 41.0 |
FGAP (only usedTourette) | - | - | 5 | 1.1 | 3 | 0.3 | 3 | 0.3 | 11 | 0.4 |
Valproate or Valpromide | - | - | 3 | 0.7 | 8 | 0.7 | 19 | 1.7 | 30 | 1.1 |
SGAP + FGAP | 2 | 4.5 | 62 | 14.1 | 262 | 23.0 | 252 | 23.3 | 578 | 21.5 |
SGAP+ Valproate or Valpromide | - | - | 1 | 0.2 | 8 | 0.7 | 8 | 0.8 | 17 | 0.6 |
FGAP+ Valproate or Valpromide | - | - | - | - | 2 | 0.2 | 8 | 0.8 | 10 | 0.3 |
Various combination | - | - | - | - | 18 | 1.2 | 32 | 3.0 | 50 | 1.8 |
FGAP/SGAP ratio | 86.3/18.1 | 68.9/44.5 | 63.2/58.6 | 60.3/58.2 | 65.1/57.1 |
Specialty
|
Only prescriber for a particular patient
|
Other prescribers are in charge of the patient
|
Total n = 2706
| |||
---|---|---|---|---|---|---|
n
|
%
|
n
|
%
|
n
|
%
| |
Hospital any type (mostly paediatricians and psychiatrists)
|
1252
|
46.3
|
729
|
26.9
|
1981
|
73.2
|
General Practice
|
309
|
11.4
|
581
|
21.5
|
890
|
32.9
|
Psychiatrist
|
250
|
9.2
|
257
|
9.5
|
507
|
18.7
|
Paediatrician
|
15
|
0.6
|
26
|
1.0
|
41
|
1.5
|
Other
|
9
|
0.3
|
52
|
1.9
|
61
|
2.3
|
No Info
|
42
|
1.6
|
164
|
6.1
|
206
|
7.6
|